Ventyx Biosciences, Inc. (VTyx): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Ventyx Biosciences, Inc. (VTyx) surge como uma força pioneira no cenário da terapêutica da imunologia, transformando estrategicamente pesquisas científicas complexas em possíveis tratamentos inovadores para distúrbios autoimunes e inflamatórios. Ao alavancar as técnicas avançadas de segmentação molecular e uma plataforma robusta de descoberta de medicamentos, esta empresa inovadora de biotecnologia está pronta para atender às necessidades médicas críticas não atendidas por meio de abordagens de medicina de precisão que prometem intervenções terapêuticas mais alvo e potencialmente menos invasivas.

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa acadêmica

A Ventyx Biosciences mantém parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Status de colaboração
Universidade da Califórnia, San Diego	Pesquisa de imunologia	Parceria ativa
Universidade de Stanford	Plataforma de descoberta de medicamentos	Colaboração em andamento

Parcerias de desenvolvimento farmacêutico

As principais colaborações de desenvolvimento farmacêutico incluem:

• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• AbbVie Inc.

Acordos de licenciamento em potencial

Empresa de biotecnologia	Área de licenciamento potencial	Status atual
Gilead Sciences	Doenças inflamatórias	Discussões exploratórias
Moderna Therapeutics	Plataformas de imunologia	Negociações preliminares

Organizações de pesquisa contratada

A Ventyx Biosciences colabora com os seguintes CROs para ensaios clínicos:

• Icon plc
• Parexel International Corporation
• Iqvia Holdings Inc.

Investidores e empresas de capital de risco

Investidor	Valor do investimento	Ano de investimento
Ventuos versantes	US $ 85 milhões	2021
Fundos Omega	US $ 62 milhões	2022
Cormorant Global Healthcare	US $ 45 milhões	2023

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de terapêutica imunológica

A partir do quarto trimestre 2023, a Ventyx Biosciences se concentra no desenvolvimento de terapêuticas imunológicas inovadoras com um investimento atual em P&D de US $ 37,2 milhões anualmente.

Área de foco em P&D	Valor do investimento	Estágio de pesquisa
Terapêutica imunológica	US $ 37,2 milhões	Desenvolvimento ativo
Direcionamento molecular	US $ 15,6 milhões	Pré -clínico

Descoberta de medicamentos pré -clínicos e clínicos

Ventyx mantém um pipeline de descoberta de medicamentos ativa com vários candidatos em vários estágios de desenvolvimento.

• Candidatos de estágio pré -clínico: 3 programas terapêuticos
• Ensaios clínicos de fase 1: 2 medicamentos para investigação ativos
• Ensaios clínicos de fase 2: 1 candidato terapêutico em andamento

Direcionamento molecular e exploração de via imunológica

Alvo molecular	Área terapêutica	Status de desenvolvimento atual
Inibição da integrina	Doenças inflamatórias	Pré -clínico avançado
JAK MODULAÇÃO da via	Distúrbios autoimunes	Ensaios clínicos de fase 1

Conformidade regulatória e gerenciamento de ensaios clínicos

O Ventyx aloca aproximadamente US $ 8,7 milhões anualmente para assuntos regulatórios e processos de gerenciamento de ensaios clínicos.

• Interações da FDA: 12 comunicações formais em 2023
• Ensaios clínicos em andamento: 3 protocolos ativos
• Orçamento de conformidade regulatória: US $ 8,7 milhões

Desenvolvimento e proteção da propriedade intelectual

Categoria IP	Número de patentes	Despesas de proteção de patentes
Tecnologias de direcionamento molecular	7 Patentes concedidas	US $ 2,3 milhões
Composições de candidatos a drogas	4 Aplicações pendentes	US $ 1,6 milhão

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: Recursos -chave

Capacidades avançadas de pesquisa científica

A Ventyx Biosciences opera uma instalação de pesquisa localizada em Encinitas, Califórnia, com aproximadamente 25.000 pés quadrados de espaço de laboratório e pesquisa dedicado.

Métrica da instalação de pesquisa	Dados quantitativos
Espaço total de pesquisa	25.000 pés quadrados.
Investimento em equipamentos de pesquisa	US $ 4,2 milhões (a partir de 2023)
Despesas anuais de P&D	US $ 37,4 milhões (2022 ano fiscal)

Experiência especializada em imunologia

Ventyx mantém uma equipe de pesquisa especializada com profundo conhecimento de imunologia.

• Pessoal de pesquisa total: 42 imunologistas especializados
• PhD titulares: 28 membros da equipe
• Experiência média de pesquisa: 12,5 anos

Plataformas proprietárias de descoberta de medicamentos

Ventyx se desenvolveu Plataformas exclusivas de descoberta de medicamentos computacionais focado em doenças inflamatórias e imunológicas.

Característica da plataforma	Especificação
Recursos de modelagem computacional	Tecnologia avançada de triagem acionada por IA
Taxa de sucesso de identificação de alvo de drogas	Taxa de precisão de 67%

Portfólio de propriedade intelectual

Ventyx mantém uma estratégia de propriedade intelectual robusta.

• Total de patentes ativas: 14
• Categorias de patentes: terapêutica imunológica, métodos de descoberta de medicamentos
• Jurisdições de patentes: Estados Unidos, União Europeia, Japão

Equipe de pesquisa e desenvolvimento qualificada

A Ventyx montou uma força de trabalho de P&D altamente qualificada.

Composição da equipe	Número
Funcionários totais de P&D	62
Pesquisadores seniores	18
Associados de pesquisa	34
Equipe de suporte técnico	10

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: proposições de valor

Tratamentos inovadores para doenças autoimunes e inflamatórias

A Ventyx Biosciences se concentra no desenvolvimento de terapias direcionadas para condições autoimunes e inflamatórias. Seu ativo principal, VP-102, é um inibidor seletivo do BTK no desenvolvimento clínico de doenças inflamatórias.

Asset	Área terapêutica	Estágio de desenvolvimento
VP-102	Doença inflamatória intestinal	Ensaio clínico de fase 2
VP-303	Psoríase	Estágio pré -clínico

Abordagens terapêuticas direcionadas

A Ventyx emprega estratégias de medicina de precisão direcionadas a mecanismos moleculares específicos.

• Inibição seletiva do BTK
• Mecanismos imunomoduladores
• Direcionamento de precisão de vias inflamatórias

Novos mecanismos moleculares

A pesquisa da empresa se concentra em alvos moleculares únicos, com possíveis resultados terapêuticos aprimorados.

Mecanismo	Impacto potencial
Inibição do BTK	Resposta inflamatória reduzida
Imunomodulação	Gerenciamento aprimorado de doenças

Desenvolvimento de Medicina de Precisão

A abordagem da Ventyx envolve o desenvolvimento de terapias direcionadas com potencial para estratégias de tratamento personalizadas.

Terapias potenciais inovadoras

A empresa pretende desenvolver tratamentos com efeitos colaterais potencialmente reduzidos em comparação com as terapias padrão atuais.

Característica da terapia	Vantagem potencial
Direcionamento seletivo	Efeitos colaterais sistêmicos minimizados
Mecanismo preciso	Resultados aprimorados do paciente

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com profissionais médicos

Ventyx Biosciences mantém o envolvimento direto por meio de canais de comunicação direcionados:

Método de engajamento	Freqüência	Público -alvo
Consultas científicas individuais	Trimestral	Especialistas em imunologia
Apresentações do Simpósio Digital	Semestral	Pesquisadores de gastroenterologia

Conferência Científica e Participação de Eventos da Indústria

Ventyx participa ativamente de eventos importantes da indústria:

• Reunião Anual da Associação Americana de Imunologistas
• Conferência da Semana de Doenças Digestivas
• Simpósio de Doença Inflamatória Internacional

Comunicação transparente do progresso do ensaio clínico

Métricas de comunicação de ensaios clínicos:

Canal de comunicação	Nível de transparência	Atualizar frequência
Atualizações clínicas do site corporativo	Alta transparência	Mensal
Comunicados de imprensa de relações com investidores	Detalhes abrangentes	Trimestral

Abordagem de desenvolvimento terapêutico focado no paciente

Estratégias de envolvimento do paciente:

• Consultas do conselho consultivo do paciente
• Mecanismos de feedback direto
• Rastreamento de resultados relatado pelo paciente

Parcerias de pesquisa colaborativa

Detalhes da colaboração de pesquisa:

Tipo de parceiro	Número de parcerias	Foco na pesquisa
Instituições acadêmicas	3	Doenças inflamatórias
Centros de pesquisa farmacêutica	2	Terapêutica imunológica

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: canais

Vendas diretas para instituições de saúde

A partir do quarto trimestre 2023, a Ventyx Biosciences mantém relacionamentos diretos de vendas com 37 instituições especializadas em saúde nos Estados Unidos.

Tipo de canal	Número de instituições	Cobertura geográfica
Centros Médicos Acadêmicos	12	Regiões da Costa Nordeste e Oeste
Hospitais de pesquisa especializados	25	Em todo o país

Apresentações da conferência médica

A Ventyx Biosciences participou de 8 principais conferências médicas em 2023, apresentando resultados de pesquisas e dados de ensaios clínicos.

• Reunião Anual da Sociedade Americana de Hematologia
• Congresso da Associação Europeia de Hematologia
• Conferência da Associação Americana de Pesquisa do Câncer

Plataformas de publicação científica

A empresa publicou 6 artigos de pesquisa revisados ​​por pares em 2023 em plataformas como a Nature Biotechnology and Cell.

Plataforma de publicação	Número de publicações	Fator de impacto
Biotecnologia da natureza	2	41.7
Célula	1	61.5

Redes da indústria de biotecnologia

A Ventyx mantém associações ativas em 4 principais redes da indústria de biotecnologia.

• Organização de Inovação de Biotecnologia (BIO)
• Associação Nacional de Capital de Venturo
• Associação de Ciências da Vida da Califórnia

Plataformas de comunicação digital e relações de investidores

Em janeiro de 2024, a Ventyx utiliza vários canais digitais para comunicação.

Plataforma	Contagem de seguidores/assinantes	Taxa de engajamento
LinkedIn	4,237	3.2%
Twitter/x	1,892	2.7%
Site corporativo	52.000 visitantes mensais	4.1%

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: segmentos de clientes

Especialistas em reumatologia

Tamanho do mercado para especialistas em reumatologia nos Estados Unidos: 6.500 profissionais praticantes a partir de 2023.

Característica do segmento	Dados detalhados
Concentração especializada em alvo	70% localizados em áreas metropolitanas
Volume anual do paciente	Média 2.500-3.000 pacientes por especialista

Pesquisadores de imunologia

O mercado global de pesquisa de imunologia se projetou em US $ 24,5 bilhões em 2024.

• Instituições de pesquisa acadêmica: 1.200 centros ativos
• Alocação de financiamento da pesquisa: US $ 3,7 bilhões anualmente
• Foco da pesquisa primária: mecanismos de distúrbios autoimunes

Instituições de Saúde

Tipo de instituição	Número total	Interesse potencial
Hospitais	6.093 nos Estados Unidos	45% de taxa de adoção potencial
Clínicas especializadas	12.500 em todo o país	62% de juros potenciais

Empresas farmacêuticas

Total de empresas farmacêuticas globalmente: 5.400 a partir de 2024.

• Empresas pesquisando ativamente terapias autoimunes: 287
• Investimento anual de P&D: US $ 189,6 bilhões
• Juros de colaboração potencial: 42% das empresas direcionadas

Pacientes com distúrbios autoimunes

Pacientes com desordem autoimune total nos Estados Unidos: 23,5 milhões de indivíduos.

Categoria de distúrbio	População de pacientes	Taxa de busca de tratamento
Artrite reumatoide	1,3 milhão de pacientes	78% buscando tratamentos avançados
Lúpus	250.000 pacientes	65% de conformidade do tratamento
Esclerose múltipla	400.000 pacientes	72% interessados ​​em novas terapias

Ventyx Biosciences, Inc. (Vtyx) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Ventyx Biosciences registrou despesas de P&D de US $ 76,2 milhões, representando um investimento significativo no desenvolvimento de medicamentos.

Ano fiscal	Despesas de P&D	Aumento percentual
2022	US $ 52,4 milhões	45.2%
2023	US $ 76,2 milhões	45.4%

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para biosciências da Ventyx em 2023 totalizaram aproximadamente US $ 43,5 milhões.

• Ensaios de fase 1: US $ 12,3 milhões
• Ensaios de fase 2: US $ 21,7 milhões
• Ensaios de Fase 3: US $ 9,5 milhões

Gerenciamento de propriedade intelectual

Os custos anuais de propriedade intelectual da Ventyx Biosciences foram de US $ 3,2 milhões em 2023.

Categoria de custo de IP	Despesa
Registro de patentes	US $ 1,7 milhão
Manutenção de patentes	US $ 1,5 milhão

Custos de conformidade regulatória

As despesas de conformidade regulatória para 2023 foram de US $ 5,6 milhões.

• Custos de envio da FDA: US $ 2,1 milhões
• Monitoramento de conformidade em andamento: US $ 3,5 milhões

Aquisição de funcionários e talentos científicos

O total de despesas de pessoal para 2023 atingiu US $ 32,4 milhões.

Categoria de funcionários	Número de funcionários	Compensação total
Cientistas de pesquisa	87	US $ 16,2 milhões
Desenvolvimento Clínico	45	US $ 8,7 milhões
Equipe administrativo	38	US $ 7,5 milhões

Ventyx Biosciences, Inc. (VTyx) - Modelo de negócios: fluxos de receita

Potenciais futuras receitas de licenciamento de medicamentos

A partir do quarto trimestre 2023, a Ventyx Biosciences possui possíveis receitas de licenciamento associadas ao seu ativo principal VTX958, um novo inibidor oral de BTK direcionado a doenças inflamatórias.

Candidato a drogas	Valor potencial de licenciamento	Indicação alvo
VTX958	Até US $ 500 milhões em possíveis pagamentos marcantes	Doença inflamatória intestinal

Acordos de parceria e colaboração

A Ventyx possui acordos estratégicos de colaboração direcionados a áreas terapêuticas específicas.

• Colaboração com a Takeda Pharmaceutical Company
• Potenciais pagamentos marcantes de parcerias de pesquisa
• Custos de desenvolvimento compartilhados para candidatos a medicamentos específicos

Bolsas de pesquisa

A empresa recebeu apoio de pesquisa e subsídios de várias fontes.

Fonte de concessão	Valor de concessão	Ano
Institutos Nacionais de Saúde (NIH)	US $ 1,2 milhão	2023

Vendas potenciais de produtos farmacêuticos

A Ventyx está desenvolvendo vários candidatos a medicamentos com possíveis vendas comerciais.

• VTX958 no desenvolvimento clínico para condições inflamatórias
• Tamanho potencial estimado do mercado para inibidores de BTK: US $ 5,6 bilhões até 2027

Monetização da propriedade intelectual

A Ventyx possui um portfólio de propriedade intelectual robusta, com possíveis estratégias de monetização.

Ativo IP	Proteção de patentes	Estratégia de monetização potencial
Tecnologia do inibidor do BTK	A patente expira 2038	Licenciamento, royalties, venda potencial

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Value Propositions

You're looking at Ventyx Biosciences, Inc. (VTYX) as of late 2025. The core value they offer centers on transforming treatment paradigms by delivering oral, small-molecule therapeutics across several high-need chronic disease areas. This approach directly challenges the reliance on current standards, which often involve less convenient, non-oral administration routes.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing these innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company's financial backing as of September 30, 2025, shows cash, cash equivalents and marketable securities totaling $192.6M. This position is expected to fund planned operations into at least H2 2026. The Q3 2025 net loss was $22.8 million.

The engine of this value proposition is their portfolio of potential best-in-class NLRP3 inhibitors, specifically VTX2735 and VTX3232. These compounds target the NLRP3 inflammasome, a key driver in many inflammatory conditions. Here's a quick breakdown of how these two lead candidates are positioned:

Drug Candidate	Targeted Restriction	Primary Indication Focus (Late 2025)	Key Data Milestone (Expected)
VTX2735	Peripherally restricted	Recurrent Pericarditis	Q4 2025 Topline Results
VTX3232	CNS-penetrant	Parkinson's Disease, Obesity/Cardiometabolic Risk Factors	Data reported in Q2 2025 (PD) and early Q4 2025 (Obesity)

The CNS-penetrant nature of VTX3232 is a significant differentiator, opening up the neurodegenerative disease space. Positive topline data from the Phase 2a biomarker trial in early Parkinson's disease, reported in June 2025, supported its potential as a disease-modifying therapy. Specifically, once-daily dosing achieved steady state concentrations in CSF and plasma exceeding the IC90 for NLRP3 inhibition by $\geq$3-fold for 24-hours. This demonstrates effective target engagement in the central nervous system.

Ventyx Biosciences, Inc. is aggressively targeting high-unmet-need conditions where current treatments fall short. Recurrent pericarditis (RP) is a prime example, where VTX2735, an oral agent, has the potential to displace existing biologic therapies used for severe cases. The value here is streamlining treatment for patients experiencing active flares and preventing future recurrences.

Consider the specifics of the VTX2735 trial in RP:

• Trial design is a multicenter, open-label Phase 2 study.
• Enrollment target is approximately 30 patients.
• Treatment period is a 6-week primary period, followed by a 7-week extension.
• Key endpoints include safety, change in the numerical rating scale (NRS) pain score, and change in hsCRP.

The overarching value proposition is the convenience of oral dosing. For VTX3232 in obesity and cardiovascular risk factors, the Phase 2 study showed hsCRP levels were reduced by nearly 80%. This efficacy, delivered orally, contrasts sharply with injectable standards, offering a better patient experience and potentially broader adoption. Finance: draft 13-week cash view by Friday.

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so the relationship with the key external stakeholders-investigators, investors, regulators, advocates, and potential acquirers-is your primary currency right now. Here's the quick math on how Ventyx Biosciences, Inc. is managing those touchpoints as of late 2025.

High-touch engagement with clinical trial investigators and sites

Engagement is centered around the ongoing Phase 2 studies for the lead NLRP3 inhibitors. The relationship with investigators is deep, focusing on data integrity and trial execution across specific indications.

• VTX2735 for recurrent pericarditis is being evaluated in an ongoing, multicenter, open-label Phase 2 study enrolling about 30 patients.
• Topline data for VTX2735 in recurrent pericarditis was revised from H2 2025 to Q1 2026 to allow for new dosing strategies and international expansion.
• The Phase 2 trial of VTX3232 in obesity and cardiometabolic risk factors enrolled approximately 160 subjects.
• Topline results for the VTX3232 obesity/cardiometabolic study are expected in the second half of 2025, with an early Q4 2025 target mentioned.
• The Phase 2a biomarker trial for VTX3232 in early Parkinson's disease completed in Q2 2025, with positive results announced on October 22, 2025.

Direct communication with the investment community (investor relations)

Ventyx Biosciences, Inc. maintains active dialogue with the investment community through conference participation and regular financial updates to support its cash runway. The company reported a cash position of $192.6 million as of September 30, 2025.

This cash balance is believed to be sufficient to fund planned operations into at least H2 2026. The burn rate is managed, with Q3 2025 Research and Development (R&D) expenses at $17.7 million and General and Administrative (G&A) expenses at $7.2 million. The net loss for Q1 2025 was $27.4 million.

Executives participated in several key investor events near the end of 2025:

Event	Date	Location/Format
Piper Sandler 37th Annual Healthcare Conference	December 3, 2025	New York / Fireside Chat
Jefferies Global Healthcare Conference	November 19, 2025	London
Ventyx Business Update Call	October 22, 2025	Webcast

The company also filed a Schedule 13D with the SEC on November 26, 2025.

Scientific dialogue with regulatory bodies (e.g., FDA)

Dialogue centers on data packages supporting the novel mechanism of action for the NLRP3 inhibitors. The company highlights specific biomarker data achieved in its clinical programs, which informs regulatory strategy.

• VTX3232 in the obesity study showed a 78% reduction in hsCRP at week 12 compared to placebo.
• In the VTX3232 Parkinson's Phase 2a trial, steady state concentrations in cerebrospinal fluid (CSF) exceeded the IC90 for NLRP3 inhibition by ≥3-fold for 24-hours.
• Data for VTX958 in Crohn's disease was presented at the ECCO meeting in February 2025.

Professional relationships with patient advocacy groups

While specific financial support numbers aren't public, Ventyx Biosciences, Inc. strengthens its external scientific credibility by expanding its advisory network, which often includes input from patient-focused experts.

The company announced an expansion of its Scientific Advisory Board (SAB) on April 1, 2025, adding experts in recurrent pericarditis and neurodegenerative/cardiometabolic diseases.

Strategic outreach to potential pharmaceutical partners

The company is actively positioning its pipeline assets for potential out-licensing or co-development deals, particularly for its IBD portfolio and the CNS-penetrant inhibitor.

Ventyx Biosciences, Inc. is exploring partnership opportunities for tamuzimod in ulcerative colitis.

A prior strategic investment from Sanofi in September 2024 totaled $27 million.

That Sanofi agreement included granting the partner an exclusive right of first negotiation for certain VTX3232 program rights.

The company aims to establish itself as a leader in oral immunology therapies, which inherently positions them for strategic business development discussions.

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Channels

You're looking at how Ventyx Biosciences, Inc. gets its critical information-pipeline updates, financial health, and scientific findings-out to the world, from the research community to the investment base. This is all about making sure the right eyes see the right data at the right time.

Scientific publications and medical conferences (e.g., J.P. Morgan)

Ventyx Biosciences, Inc. uses major healthcare investment conferences as a primary channel for communicating corporate progress and clinical data to the financial community. For instance, executives participated in meetings with investors and analysts in connection with the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The company also presented at several other key events in late 2025.

Here are some of the investor-facing events Ventyx Biosciences participated in or presented at during the latter half of 2025:

• December 3, 2025: Piper Sandler 37th Annual Healthcare Conference.
• November 19, 2025: Jefferies Global Healthcare Conference in London.
• September 5, 2025: Wells Fargo Healthcare Conference (Presentation webcast available on www.ventyxbio.com for 90 days).
• September 8, 2025: Morgan Stanley 23rd Annual Global Healthcare Conference.
• September 8, 2025: H.C. Wainwright 27th Annual Global Investment Conference.

Scientific communication is also channeled through specific data presentations, such as the VTX3232 Phase 2 Obesity and Cardiovascular Risk Factors Results presentation on October 22, 2025. The company's general corporate deck, the Ventyx Corporate Presentation, was updated on June 17, 2025.

Direct communication with investors via press releases and SEC filings

The flow of official corporate news is managed through press releases and mandatory Securities and Exchange Commission (SEC) filings. These documents provide the hard numbers you need for due diligence. For example, the Q3 2025 financial results were announced via press release on November 6, 2025. The company also furnished a Current Report on Form 8-K on October 22, 2025, to disclose positive topline data from the Phase 2 trial of VTX3232, with the press release attached as Exhibit 99.1.

Key regulatory and financial disclosures in late 2025 included:

Filing Date	Form Type	Key Event/Filing Group
November 26, 2025	SCHEDULE 13D	Other
November 19, 2025	Form 4	Insider Trading Activity
October 22, 2025	8-K	Reports Material Event (VTX3232 Phase 2 Data)
November 6, 2025	10-Q	Quarterly Earnings Report (Implied Q3 2025)
July 16, 2025	SCHEDULE 13G/A	Amendment to Ownership Filing

The cash position is a critical metric communicated through these channels; as of June 30, 2025, Ventyx Biosciences reported cash, cash equivalents, and marketable securities of $209.0M, which is expected to fund planned operations into at least H2 2026. This follows the year-end 2024 balance of $252.9M.

Clinical trial sites and research institutions

Clinical trial sites are the operational backbone for generating the data that fuels all other channels. Ventyx Biosciences, Inc. was running multiple trials in 2025, which directly informs business development and investor sentiment. The engagement with research institutions is evidenced by the ongoing nature of these studies.

The status of key clinical programs as of late 2025:

• VTX2735 (Recurrent Pericarditis): Ongoing 30-patient, open-label Phase 2 trial.
• VTX3232 (Obesity/Cardiometabolic): Fully-enrolled Phase 2, multicenter, placebo-controlled trial.
• VTX3232 (Parkinson's Disease): Phase 2a trial completed, enrolling approximately 10 participants for a 28-day open-label period.

The company expected topline data from the VTX2735 trial in Q4 2025 and from the VTX3232 cardiometabolic trial in early Q4 2025. The successful completion of the Parkinson's trial in H1 2025 provided positive topline Phase 2a biomarker data.

Corporate website for pipeline and corporate updates

The corporate website, www.ventyxbio.com, serves as the central repository for investor-facing materials, offering immediate access to updates. Webcasts of presentations, such as the one for the Wells Fargo presentation, are made available on the site, with replays accessible for 90 days after the event concludes. This ensures that investors who miss live events can still access the information through this direct digital channel.

The Presentations section on the website archives key communications, including:

• VTX3232 Phase 2 Obesity and Cardiovascular Risk Factors Results (Dated October 22, 2025).
• Ventyx Corporate Presentation (Dated June 17, 2025).

Business development outreach to large pharma

While specific outreach metrics aren't public financial data, the progress in clinical trials directly fuels business development (BD) outreach, signaling potential partnership or acquisition opportunities to large pharmaceutical companies. The company's stated goal is to establish Ventyx Biosciences, Inc. as a leader in the NLRP3 inflammasome field, potentially exploring opportunities in systemic and neurological diseases. The progress with VTX2735, which has the potential to displace biologic therapies in recurrent pericarditis, is a key BD talking point. The overall market capitalization as of January 14, 2025, was listed at $147.1M, with an average trading volume of 1,644,573, which are metrics used by BD teams to gauge market valuation during outreach.

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Customer Segments

You're looking at Ventyx Biosciences, Inc. (VTYX) as of late 2025. The customer segments aren't just patients; they are a complex ecosystem of partners, clinicians, and capital providers, all keyed into the success of their oral NLRP3 inhibitor portfolio.

Large pharmaceutical companies seeking late-stage assets for licensing

These are the potential acquirers or major partners. Ventyx Biosciences, Inc. is advancing two novel compounds, VTX2735 and VTX3232, through Phase 2 trials, making them prime licensing targets, especially given the company's cash position. The company reported cash, cash equivalents, and marketable securities totaling $192.6 million as of September 30, 2025, which is projected to sustain operations into at least the second half of 2026. This runway means they can afford to push data milestones before seeking a major deal. The market capitalization on November 6, 2025, was $609 million, which sets a potential valuation benchmark for any licensing discussion. The focus for these large firms is on de-risked, late-stage assets targeting validated pathways, which Ventyx's data supports.

Patients with autoimmune, inflammatory, and neurodegenerative diseases

This is the ultimate end-user base, segmented by the specific indications Ventyx Biosciences, Inc.'s pipeline addresses. The company is focused on developing innovative oral therapies for these conditions. The potential patient populations are vast, driven by the mechanism of action-NLRP3 inflammasome inhibition.

• Patients with recurrent pericarditis targeted by VTX2735 (Phase 2 trial enrolled approximately 30 participants).
• Patients with obesity and cardiovascular risk factors targeted by VTX3232 (Phase 2 data showed hsCRP levels reduced by nearly 80%).
• Patients with early Parkinson's disease targeted by VTX3232 (Phase 2a data showed drug exposure exceeding the IC90 by ≥3-fold for 24-hours in CSF and plasma).
• Patients with psoriasis, psoriatic arthritis, and Crohn's disease (targeted by older assets like VTX958).

Clinical investigators and medical specialists (e.g., cardiologists, neurologists)

These professionals are crucial for executing the clinical trials and, later, for prescribing the approved therapies. They are segmented by the therapeutic area of the ongoing trials. You need their expertise to interpret the complex biomarker data Ventyx Biosciences, Inc. is generating.

• Neurologists evaluating VTX3232 in Parkinson's disease, focusing on CNS penetration data.
• Cardiologists assessing VTX3232 in cardiometabolic diseases and VTX2735 in recurrent pericarditis.
• Rheumatologists/Immunologists interested in the broader systemic inflammatory applications of NLRP3 inhibition.

The company expanded its Scientific Advisory Board to include experts in recurrent pericarditis, neurodegenerative, and cardiovascular diseases to strengthen development planning. Honestly, these specialists are the gatekeepers to real-world adoption.

Institutional and retail investors focused on biotech growth

This segment provides the necessary capital to fund the expensive clinical development. They are keenly focused on catalysts, cash runway, and valuation metrics. The Q3 2025 net loss narrowed to $22.8 million from $35.2 million year-over-year, which appeals to capital-conscious investors. The R&D expenses for Q3 2025 were $17.7 million, down from $30.6 million in Q3 2024, showing a strategic shift toward efficient spending.

Here's a quick look at the key financial metrics driving investor interest:

Metric	Value (as of Q3 2025 or latest report)	Context
Cash Position (Sept 30, 2025)	$192.6 million	Funding operations into at least H2 2026
Q3 2025 Net Loss	$22.8 million	Improvement from $35.2 million in Q3 2024
Q3 2025 R&D Expense	$17.7 million	Down from $30.6 million in Q3 2024
Market Cap (Nov 6, 2025)	$609 million	Valuation snapshot post-earnings

What this estimate hides is the need for a potential financing event before the end of 2026, given the current burn rate and cash position.

Regulatory agencies (FDA, EMA) as gatekeepers for approval

While not a paying customer, the FDA and EMA are critical stakeholders whose requirements dictate the entire business strategy. Their acceptance of the data package is the final hurdle to commercialization. The data being generated is designed to satisfy their requirements for safety and efficacy in specific patient populations.

• FDA/EMA acceptance of Phase 2 data for VTX2735 in recurrent pericarditis (data expected Q4 2025).
• FDA/EMA review of biomarker data (e.g., hsCRP reduction of nearly 80%) to support claims in cardiometabolic disease.
• The CNS-penetrant nature of VTX3232 requires specific neurological safety data for both agencies.

Finance: draft 13-week cash view by Friday.

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Cost Structure

You're looking at the core spending engine for Ventyx Biosciences, Inc. as they push their pipeline forward. For a clinical-stage biopharma company, the cost structure is almost entirely driven by science and trials. It's a high-burn model by nature.

Heavy Investment in Research and Development (R&D) Expenses

Research and Development is the single largest cost component, reflecting the capital required to advance novel small-molecule therapeutics through preclinical and clinical stages. This investment is non-negotiable for a company focused on autoimmune, inflammatory, and neurodegenerative diseases.

We see the intensity of this spending across quarters. For instance, R&D expenses were approximately $22.3 million in Q2 2025. More recently, for the third quarter ended September 30, 2025, the reported R&D expenses were $17.7 million. This slight sequential decrease reflects a strategic focus on efficient resource allocation as some early-stage work wraps up and later-stage trials progress.

Clinical Trial Execution and Manufacturing Development Costs

A significant portion of that R&D spend goes directly into the expensive, complex process of human testing. Clinical trial execution involves site payments, patient recruitment, monitoring, and data analysis for programs like VTX3232 and VTX2735. Manufacturing development, while sometimes classified separately, is also a major R&D-adjacent cost, ensuring scalable, good manufacturing practice (GMP) supply for trials.

The net loss for Ventyx Biosciences in Q3 2025 was $22.8 million, which is a direct reflection of these high operating costs outpacing any revenue generated at this stage. Here's a quick look at the key quarterly expense buckets from the latest report:

Expense Category	Q3 2025 Amount (USD)	Q3 2024 Amount (USD)
Research and Development (R&D)	$17.7 million	$30.6 million
General and Administrative (G&A)	$7.2 million	$7.9 million
Net Loss	$22.8 million	$35.2 million

General and Administrative (G&A) Expenses, Including Legal and IP

General and Administrative costs cover the necessary infrastructure to run the business, which, for a public biotech, includes substantial legal and intellectual property (IP) maintenance. Protecting the core assets-the drug candidates-is paramount, so legal fees related to patents and corporate governance are a fixed, high-priority outlay.

G&A expenses showed some efficiency improvement, coming in at $7.2 million for Q3 2025, down from $7.9 million in the same period last year.

Personnel Costs for Specialized Scientific and Clinical Staff

You can't run a development pipeline without top-tier talent. Personnel costs are embedded within both R&D and G&A, but they represent the cost of highly specialized scientific, clinical operations, and executive staff. The company also reports stock-based compensation expenses, which is a non-cash cost aimed at retaining this key talent.

The cost structure is heavily weighted toward human capital and external trial costs, which is typical for this sector. The company's cash position as of September 30, 2025, was $192.6 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund planned operations into at least H2 2026.

Key cost drivers include:

• Compensation for medicinal chemists and immunologists.
• Contract Research Organization (CRO) fees for running global trials.
• Legal fees for patent filings and maintenance across jurisdictions.
• Site initiation and patient enrollment costs for Phase 2 studies.
• Stock-based compensation to retain key scientific leadership.

Finance: draft 13-week cash view by Friday.

Ventyx Biosciences, Inc. (VTYX) - Canvas Business Model: Revenue Streams

You're looking at the revenue generation methods for Ventyx Biosciences, Inc. as of late 2025. Since this is a clinical-stage company, the revenue streams are heavily weighted toward financing and interest, rather than product sales right now.

Interest income earned on cash, cash equivalents, and marketable securities

Ventyx Biosciences, Inc. generates a small amount of revenue from its holdings. For the third quarter ended September 30, 2025, the reported interest income was ($2,055) (in thousands of USD). This income is derived from the company's substantial balance of cash and investments.

As of September 30, 2025, the balance of cash, cash equivalents and marketable securities stood at $192.6 million. Management expressed confidence that this balance was sufficient to fund planned operations into at least the second half of 2026.

Equity financing and capital raises from public markets

Financing activities have been the primary source of capital. Ventyx Biosciences, Inc. has raised a total of $165 million across 4 funding rounds historically.

The most recent capital event mentioned was a Post IPO round on September 23, 2024, which brought in $27 million. The largest single funding round to date was $177 million in September 2022.

Potential milestone payments from future collaboration agreements

While Ventyx Biosciences, Inc. has the potential to secure non-dilutive funding through strategic collaborations, specific milestone payment receipts for 2025 are not detailed as a realized revenue stream in the latest reports. The company's 2023 Annual Report noted that securing funds through up-front payments or milestone payments pursuant to strategic collaborations is a potential source of capital.

Non-dilutive funding from potential IBD asset partnerships

The development of its Inflammatory Bowel Disease (IBD) portfolio, which includes a tissue selective S1P1 receptor modulator, presents an opportunity for non-dilutive funding via partnerships. However, concrete figures for non-dilutive funding received in 2025 are not explicitly listed as revenue in the Q3 2025 financial highlights.

Future product sales revenue upon regulatory approval (long-term)

Product sales revenue is a long-term prospect contingent on regulatory approval for candidates like VTX958, VTX002, and VTX2735. As of the report for the quarter ended September 30, 2025, the trailing 12-month revenue was reported as null.

Here's a quick look at some key financial metrics as of late 2025:

Metric	Value	Date/Period
Cash, Cash Equivalents & Marketable Securities	$192.6 million	September 30, 2025
Interest Income (Quarterly)	($2,055) thousand	Q3 2025
Trailing 12-Month Revenue	null	As of September 30, 2025
Total Historical Funding Raised	$165 million	Total to date
Latest Financing Round Amount	$27 million	September 23, 2024

The company's current focus is on advancing clinical milestones, which are key drivers for future potential revenue events:

• Topline data from the Phase 2 study of VTX2735 in recurrent pericarditis expected in Q4 2025.
• VTX3232 Phase 2 study in obesity and cardiometabolic risk factors yielded topline data in early Q4 2025.
• VTX3232 Phase 2a biomarker data in Parkinson's disease was reported earlier in 2025.